EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance

Ayalew Tefferi iD, Maymona Abdelmagid, Giuseppe G Loscocco iD, Saubia Fathima, Kebede H Begna iD, Aref Al-Kali iD, James Foran, Jeanne Palmer, Talha Badar iD, Mrinal M Patnaik iD, Kaaren K Reichard, Rong He iD und 9 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Ayalew Tefferi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical relevance of TP53 mutations ( TP53 MUT ) in myeloproliferative neoplasms (MPN) and their prognostic interaction with MPN subtype designation has not been systematically studied. In the current study, 114 patients with MPN harboring TP53 MUT (VAF ≥ 2%) were evaluated for overall survival (OS), calculated from the time of TP53 MUT detection: chronic phase myelofibrosis (MF‐CP; N = 61); blast‐phase (MPN‐BP; N = 31) or accelerated‐phase (MPN‐AP; N = 16) MPN, and polycythemia vera/essential thrombocythemia (PV/ET; N = 6). Sixty‐five (57%) patients harbored International Consensus Classification (ICC)‐defined multihit TP53 MUT and 56 (49%) monosomal/complex karyotype (MK/CK). Majority of MPN‐BP (90%) and MPN‐AP (81%) while 39% of MF‐CP and none of PV/ET patients harbored multihit TP53 MUT . OS in MPN‐BP and MPN‐AP was equally dismal (median 6 vs. 4.5 months, respectively; p = 1.0), regardless of multihit configuration ( p = 0.44), while OS in TP53 MUT MPN‐BP/AP ( N = 47; median 4 months) was inferior to that of a separate cohort ( N = 49) with TP53 wild‐type MPN‐BP/AP (median 11 months; p < 0.01). OS in MF‐CP was significantly shorter with multihit versus non‐multihit TP53 MUT (median 10 vs. 35 months; HR 2.9; p < 0.01), independent of other MF‐relevant genetic risk factors, including ASXL1/SRSF2/U2AF1 mutations. Multihit TP53 MUT was also associated with inferior survival following allogeneic stem cell transplant (ASCT): median 9 months versus “not reached” in patients with ( N = 9) versus without ( N = 8) multihit TP53 MUT ( p < 0.01). The presence of multihit or non‐multihit TP53 MUT in MPN‐BP/AP or multihit TP53 MUT in MF‐CP is associated with exceptionally poor prognosis and justifies inclusion into the ICC category of “myeloid neoplasms with mutated TP53 .” By contrast, detection of non‐multihit TP53 MUT , by itself, might not endanger short‐term survival in MF‐CP, PV, or ET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersTumor Suppressor Protein p53MutationHumansFemaleMaleMiddle AgedAgedPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

ICCWHOkaryotypeprognosissurvival

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
  • Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Hematology, Mayo Clinic, Scottsdale, ARZ, USA.
  • Department of Pathology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
  • Department of Pathology, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Ayalew Tefferi, Giuseppe G Loscocco, Kebede H Begna, Aref Al-Kali, Talha Badar, Mrinal M Patnaik, Rong He, Cinthya J Zepeda Mendoza, Mithun Shah, Attilio Orazi, Daniel A Arber, Animesh Pardanani, Alessandro M Vannucchi, Devendra Hiwase, Naseema Gangat

Zitieren

APA

Tefferi, A., Abdelmagid, M., Loscocco, G. G., Fathima, S., Begna, K. H., Al-Kali, A., Foran, J., Palmer, J., Badar, T., Patnaik, M. M., Reichard, K. K., He, R., Zepeda Mendoza, C. J., Shah, M., Orazi, A., Arber, D. A., Pardanani, A., Vannucchi, A. M., Hiwase, D., …, & Guglielmelli, P. (2025). TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance. American Journal of Hematology. https://doi.org/10.1002/ajh.27609

Vancouver

Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, et al. TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance. American Journal of Hematology. 2025. doi:10.1002/ajh.27609

BibTeX
@article{Tefferi2025,
  author = {Tefferi, Ayalew and Abdelmagid, Maymona and Loscocco, Giuseppe G and Fathima, Saubia and Begna, Kebede H and Al-Kali, Aref and Foran, James and Palmer, Jeanne and Badar, Talha and Patnaik, Mrinal M and Reichard, Kaaren K and He, Rong and Zepeda Mendoza, Cinthya J and Shah, Mithun and Orazi, Attilio and Arber, Daniel A and Pardanani, Animesh and Vannucchi, Alessandro M and Hiwase, Devendra and Gangat, Naseema and Guglielmelli, Paola},
  title = {TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27609}
}
Kostenlos starten →